BackIPO Calendar: Upcoming US IPOs
Tickers, price ranges and expected dates for upcoming and recently priced US IPOs — updated weekly
31/07/2026
A running list of upcoming and recently priced US IPOs, updated weekly. Dates, price ranges and deal sizes change frequently ahead of pricing — treat the table below as a snapshot as of August 3, 2026, and confirm details before making any decision.
Upcoming and Recent IPOs
| Company | Ticker | Price Range | Est. Deal Size | Expected Date |
|---|---|---|---|---|
| Apnimed | APMD | $16.00 | $192.0M | Priced 7/31/2026 |
| Churchill Capital XIII (SPAC) | XIIIU | $10.00 | $360.0M | Priced 7/31/2026 |
| East West Ave Acquisition Corp. (SPAC) | EWAVU | $10.00 | $100.0M | Priced 7/31/2026 |
| ARC Group Securities Acquisition I (SPAC) | FJDIU | $10.00 | $105.0M | 8/4/2026 |
| BOA Acquisition Corp. II (SPAC) | THEOU | $10.00 | $125.0M | 8/4/2026 |
| Attovia Therapeutics | ATTO | $15.00–$17.00 | $200.0M | 8/5/2026 |
| Braveheart Bio | BRVE | $15.00–$17.00 | $300.0M | 8/6/2026 |
| Vogenx | VOGX | $11.00–$13.00 | $75.0M | 8/6/2026 |
| Web3Labs Global | MDAT | $4.00–$5.00 | $28.1M | Week of 8/7/2026 |
| BW Industrial Holdings | BWGC | $6.00–$7.00 | $17.1M | Week of 8/10/2026 |
| MetaOptics (uplisting) | MOT | $5.00–$7.00 | $18.0M | Week of 8/10/2026 |
| Riku Dining Group | RIKU | $4.00–$6.00 | $25.0M | Week of 8/10/2026 |
What to Watch
- A biotech IPO wave lands this week. Attovia Therapeutics prices Wednesday (8/5), and Braveheart Bio and Vogenx both price Thursday (8/6), together targeting over $500 million raised. Braveheart is developing an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; Attovia is testing a therapy for chronic itch conditions targeting the IL-31 pathway. Three biotechs pricing in the same window is typically a sign that bankers see a receptive window for the sector — it can close quickly if early deals price or trade poorly.
- Four SPACs in the mix. Churchill Capital XIII and East West Ave Acquisition Corp. already priced Friday; ARC Group Securities Acquisition I and BOA Acquisition Corp. II are set to price Tuesday (8/4). These are blank-check companies — they raise money first and identify an acquisition target later, a fundamentally different risk profile from a standard operating-company IPO.
- Private markets are opening up too. Fintech broker Clear Street launched a platform this week giving accredited investors indirect pre-IPO exposure to Databricks (last valued near $188 billion), with plans to add up to 30 late-stage private companies by year-end — a reminder that pre-IPO access is expanding well beyond the public IPO calendar.
Fact vs. estimate: tickers, price ranges and deal sizes reflect terms as filed/marketed at time of writing and can change before pricing. Expected dates for deals not yet priced are estimates.
Why It Matters for Pre-IPO and Tokenized Equity Investors
Most names on a public IPO calendar are companies that were pre-IPO investments not long ago. Watching which sectors are actively pricing (biotech this week, SPACs persistently active through 2026) is a useful read on where public-market appetite currently sits — and by extension, which categories of still-private companies may find a receptive IPO window if they choose to list next.
This material is for informational purposes only and does not constitute individual investment advice.
Sources
Calls within Tajikistan are free
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.